ONCSQ (OncoSec Medical) Ending Cash Position: $3.68 Mil (As of Jan. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is OncoSec Medical Ending Cash Position?

OncoSec Medical ONCSQ -99.00% Ending Cash Position is $3.68 Mil as of Jan. 2023.

OncoSec Medical's Ending Cash Position for the quarter that ended in Jan. 2023 was $3.68 Mil.

OncoSec Medical's quarterly Ending Cash Position declined from Jul. 2022 ($12.30 Mil) to Oct. 2022 ($5.73 Mil) and declined from Oct. 2022 ($5.73 Mil) to Jan. 2023 ($3.68 Mil).

OncoSec Medical's annual Ending Cash Position increased from Jul. 2020 ($20.35 Mil) to Jul. 2021 ($45.95 Mil) but then declined from Jul. 2021 ($45.95 Mil) to Jul. 2022 ($12.30 Mil).

OncoSec Medical Ending Cash Position Related Terms

OncoSec Medical Ending Cash Position Historical Data

* Premium members only.

The historical data trend for OncoSec Medical's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OncoSec Medical Ending Cash Position Chart

OncoSec Medical Annual Data
Trend Jul13 Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.80 25.15 20.35 45.95 12.30

OncoSec Medical Quarterly Data
Apr18 Jul18 Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 25.23 19.48 12.30 5.73 3.68

OncoSec Medical Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

OncoSec Medical's Ending Cash Position for the fiscal year that ended in Jul. 2022 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=45.952+-33.652
=12.30

OncoSec Medical's Ending Cash Position for the quarter that ended in Jan. 2023 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=5.718+-2.035
=3.68

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $3.68 Mil mean?
OncoSec Medical (ONCSQ) has a Ending Cash Position of $3.68 Mil as of Jan. 2023. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on OncoSec Medical and its competitors.
Is OncoSec Medical's Ending Cash Position too high?
OncoSec Medical's current Ending Cash Position is $3.68 Mil.
How does OncoSec Medical's Ending Cash Position compare to NOVNQ and USRM?
OncoSec Medical's Ending Cash Position of $3.68 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on OncoSec Medical and its competitors. OncoSec Medical's current Ending Cash Position is $3.68 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OncoSec Medical stock overvalued right now?
OncoSec Medical (ONCSQ) has a current Ending Cash Position of $3.68 Mil. The current Ending Cash Position is $3.68 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For OncoSec Medical (ONCSQ), the current Ending Cash Position is $3.68 Mil as of Jan. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

OncoSec Medical Business Description

Address 820 Bear Tavern Road, Ewing, NJ, USA, 08628-1021
OncoSec Medical Inc is a healthcare sector company. It is focused on designing, developing and commercializing gene therapies, therapeutics, and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The company's lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation. In addition, it is pursuing ImmunoPulse IL-12 monotherapy in patients with triple-negative breast cancer.